Ellington Management Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Ellington Management Group’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,820	Closed	-$382K	–	934
2018 Q1	$382K	Buy	5,820 +3,180	+120%	+$240K	0.03%	495
2017 Q4	$222K	Buy	+2,640	New	+$259K	0.04%	453
2016 Q2	–	Sell	-1,280	Closed	-$120K	–	528
2016 Q1	$120K	Buy	+1,280	New	+$139K	0.05%	458
2015 Q4	–	Sell	-1,538	Closed	-$223K	–	874
2015 Q3	$223K	Buy	+1,538	New	+$282K	0.06%	535

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellington Management Group's BLCM Position: Q2 2018 in Review

Ellington Management Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 5,820 shares — an estimated $382K sold.

Ellington Management Group first reported a position in BLCM in Q3 2015 and held it in 4 quarters. The position peaked at $382K in Q1 2018. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

Ellington Management Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Ellington Management Group sold 5,820 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $382K.
Ellington Management Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 4 quarters.
Ellington Management Group's Bellicum Pharmaceuticals, Inc. position peaked at $382K in Q1 2018.
96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.